A Phase 2 interventional study of Brincidofovir in Ebola Virus Disease, sponsored by Chimerix. Withdrawn. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-02-26.
Sponsored by Chimerix · Phase 2, Interventional, and Treatment
The purpose of this study is to determine how safe and tolerable Brincidofovir (BCV) is when given for post exposure prophylaxis of Ebola virus disease.
The primary objective of this study is to evaluate the safety and tolerability of BCV when administered for post-exposure prophylaxis of EVD
914 studies on the registry are indexed under Virus Diseases; 110 are open to participants now.
Browse Virus Diseases studies →Chimerix is the lead sponsor of 33 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 6 (86%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
-
Initial dose of 200mg followed by 4 doses of 100mg
Drug: Brincidofovir
Also known as: CMX001
The primary objective of this study is to evaluate the safety and tolerability of BCV when administered for post-exposure prophylaxis of EVD
Time frame: 8 weeks
To assess the effect of BCV treatment on development of EVD in subjects through 21 days post-initiation of BCV therapy
Time frame: 8 weeks
No study locations are listed for this record.
This study is withdrawn, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chimerix